COVID-19

HonorHealth Research Institute quickly launched several clinical trials in response to the COVID-19 pandemic. One was the first in the nation to study atovaquone and azithromycin, a combination which may have fewer cardiac side effects than other treatments. Another was the first in Arizona to evaluate a novel drug to improve pulmonary symptoms and recovery and avoid the need for mechanical ventilation. HonorHealth Research Institute also enrolled the first patient in the Southwest in a study of ruxolitinib, a drug with the potential to reduce the time some COVID-19 patients spend on ventilators.